Zhi Tong Cai Jing·2025-11-18 08:41Core Insights - The company has signed a memorandum of understanding with Yunnan Watson Bio-Technology Co., Ltd. to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform [1][2] - The memorandum outlines a two-year collaboration period and includes joint development, clinical trials, registration, and sales and distribution [1] Group 1 - The partnership aims to leverage complementary strengths to enhance the company's position in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - The collaboration will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform is expected to facilitate cross-border investment opportunities, enhance corporate visibility, and deepen research and development capabilities [2] Group 2 - The partnership will establish an RNA-focused research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology [1] - Clinical trials and regulatory approvals for existing and pipeline products will be expedited in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve ASEAN and specific international markets [1]